Compositions and methods for treating cavity conditions

• US 8,153,112 B2
• Filed: 08/03/2007
• Issued: 04/10/2012
• Est. Priority Date: 08/03/2007
• Status: Active Grant

• Current Assignee: Warsaw Orthopedic Incorporated (Medtronic Plc)
• Original Assignee: Warsaw Orthopedic Incorporated (Medtronic Plc)
• Inventors: Drapeau, Susan J., Shimko, Daniel Andrew, Roy, Josée
• Primary Examiner(s): Lundgren, Jeffrey S.
• Assistant Examiner(s): Bori, Ibrahim D
• Application Number:
  US11/890,154
• Publication Number:
  US 20090035250A1
• Time in Patent Office: 1,712 Days
• Field of Search: 424/78.31, 424/682, 424/422, 424/426
• US Class Current: 424/78.3
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/74 Synthetic polymeric materials
• CPC Class Codes: A61K 31/77 of oxiranes
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compositions, methods and kits to be used as a lubricant and for treatment of a cavity pathology including joint pathology are provided. The composition comprises therapeutically effective amounts of at least one bioactive agent, such as magnesium compound, at least one lubricating agent, such as hyaluronic acid, and at least one cell membrane repairing agent, such as polyethylene glycol. The components of these compositions may be administered by a direct application, an application through a cannula, an intra-articular injection, as a flush fluid during an arthroscopy of the affected area, as a post-arthroscopy injection, or as part of a lavage of the area affected by the intra-articular pathology. In addition, the composition of the present invention may be administered to the patient from a pump or a depot.

Claims

1. A therapeutic composition comprising therapeutically effective amounts of at least one bioactive agent comprising a magnesium compound in the range of about 0.01 to 15% weight to volume;

at least one lubricating agent comprising a hyaluronic acid in the range of about 0.05 to 50% weight per volume;

at least one cell membrane repairing agent comprising polyethylene glycol (PEG) in the range of about 0.05 to 50% weight to volume; and

at least one antioxidant in the range of about 0.00003 to 0.3% weight per volume.

2. The therapeutic composition of claim 1, wherein the composition is used to treat a joint pathology.

3. The therapeutic composition of claim 1 wherein the composition is used to lubricate synovial, fibrous and cartilaginous joints.

4. A method of treating a cavity pathology comprising administering a therapeutically effective amount of therapeutic composition of claim 1 to the affected area.

5. A method of lubricating a joint, comprising administering a therapeutically effective amount of therapeutic composition of claim 1 to the joint.

19. The therapeutic composition of claim 1, wherein the at least one antioxidant is in the range of about 0.001 to 0.03% weight per volume.

6. A method of treating a cavity pathology comprising administering to the affected area a composition comprising therapeutically effective amounts of at least one bioactive agent comprising a magnesium compound in the range of about 0.01 to 15% weight to volume;

at least one cell membrane repairing agent comprising polyethylene glycol (PEG) in the range of about 0.05 to 50% weight to volume;

at least one lubricating agent comprising hyaluronic acid in the range of about 0.05 to 50% weight per volume; and

at least one antioxidant in the range of about 0.00003 to 0.3% weight per volume.

7. The method of claim 6, wherein the step of administering the composition comprises administering the composition by a method selected from the group consisting of a direct application, an application through a cannula, intra-articular injection, a lavage of affected area, flush of the affected area, flush fluid during an arthroscopy of the affected area, post-arthroscopy injection of the affected area or combinations thereof.

8. The method of claim 6, wherein the composition is administered from a depot.

9. The method of claim 6, wherein the composition is administered by a pump.

10. The method of claim 6, further comprising the step of delivering at least one marker with the composition.

11. The method of claim 6, wherein the cavity pathology is caused by a disease selected from the group consisting of a degenerative disease, an autoimmune disease, and an acute or chronic condition.

12. The method of claim 6, wherein the cavity pathology is associated with an or acute or chronic condition selected from the group consisting of an injury, an invasive medical intervention, a degenerative disease, and a lack of natural lubricants.

13. The method of claim 6, wherein the cavity pathology affects a joint selected from the group consisting of spinal disc;

elbow, wrist, finger, hip, knee, ankle, toe, skull, pelvis, spinous processes, vertebrae, spine, ribs and clavicle.

20. The method of claim 6, wherein the at least one antioxidant is in the range of about 0.001 to 0.03% weight per volume.

14. A therapeutic kit comprising at least one bioactive agent comprising a magnesium compound in the range of about 0.01 to 15% weight to volume;

at least one cell membrane repairing agent comprising polyethylene glycol (PEG) in the range of about 0.05 to 50% weight to volume;

at least one lubricating agent comprising hyaluronic acid in the range of about 0.05 to 50% weight per volume;

at least one antioxidant in the range of about 0.00003 to 0.3% weight per volume; and

a set of instructions comprising information on making a lubricant composition.

15. The kit of claim 14, wherein the at least one cell membrane repairing agent comprises PEG.

16. The kit of claim 14, wherein the at least one bioactive agent comprises a magnesium compound.

17. The kit of claim 14, wherein the at least one lubricating agent comprises a hyaluronic acid.

18. The kit of claim 14, wherein the set of instructions comprises information on preparing a direct application, an application through a cannula, an intra-articular injection, solution for a lavage of the area affected by the joint pathology, a flush fluid for use during an arthroscopic surgery, a post-arthroscopy injection, or combinations thereof.

21. The kit of claim 14, wherein the at least one antioxidant is in the range of about 0.001 to 0.03% weight per volume.